Sun Pharmaceutical and its Taro Pharmaceutical subsidiary are washing their hands of another segment of a years-long antitrust debacle with a $200 million settlement. The deal will clear all claims ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results